[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Oral Presentations: American Head and Neck Society
August 2006

S070 Phase 2 Study of Combretastatin A4 Phosphate (CA4P) in Patients With Advanced Anaplastic Thyroid Carcinoma (ATC)

Arch Otolaryngol Head Neck Surg. 2006;132(8):854. doi:10.1001/archotol.132.8.854-a

CASE Comprehensive Cancer Center, Cleveland, Ohio;

University of Pittsburgh Cancer Institute, Pittsburgh, Pa

Background: Combretastatin A4 phosphate (CA4P) is the first tubulin-binding vascular-disrupting agent tested in the clinic. Phase I studies demonstrated activity in anaplastic thyroid carcinoma (ATC).

Methods: Patients with metastatic ATC, good performance status, normal electrocardiographic and cardiac function, and no prior therapy for disseminated disease were eligible for study. CA4P at a dose of 45 mg/m2 was administered as a 10-minute intravenous infusion on days 1, 8, and 15 every 28 days (1 cycle).

First Page Preview View Large
First page PDF preview
First page PDF preview